PubMed Health⌕ Search

Biomedical subjects

P Pryde

Publications and source records attributed to P Pryde.

6 recordsLinked to original sources

Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States.

BACKGROUND: Previous studies have shown socioeconomic disparities in the use of prenatal diagnosis in several countries, including France and the United States. Few studies however, have examined the impact of socioeconomic differences in prenatal testing on disparities in the live birth prevalence of congenital anomalies. In this article, we first review and further discuss some of the results of our previously published work that assesses: i) socioeconomic differences in the use of amniocentesis in the United States using data from national birth cohorts; and ii) impact of socioeconomic differences in prenatal diagnosis on the live birth prevalence of Down's syndrome (trisomy 21). We then present the results of a study that explores the potential effects of public policies regarding abortion on state-level differences in the live birth prevalence of Down's syndrome. MATERIALS AND METHODS: We used birth data from the National Center for Health Statistics for the years 1989 to 1991 as well as data from the National Abortion and Reproductive Rights Action League (NARAL) state-by-state review of abortion rights. The main individual-level socioeconomic variables in the analyses were maternal ethnicity and education; the analyses of the interaction effects between maternal age and ethnicity are presented here. Interaction effects were assessed using logistic regression models with likelihood ratio tests. We used hierarchical logistic regression models for analyses of state-level effects while controlling for individual-level socioeconomic factors. RESULTS: We found substantial age-specific socioeconomic differences in the use of amniocentesis and in the rates of age-related increase in the live birth prevalence of Down's syndrome. In particular, African Americans and Mexican Americans were found to have lower odds of amniocentesis use and higher odds of Down's syndrome at birth. In addition, after controlling for maternal age, socioeconomic factors and prenatal care, we found that states which allowed public financing of abortion services for all or most circumstances had lower odds of Down's syndrome at birth. CONCLUSION: Unless socioeconomic differences in prenatal testing are addressed, the increasing use of prenatal testing might result in widening socioeconomic disparities in the live birth prevalence of Down's syndrome and other major congenital anomalies in future years.

Abortion, Induced↗

Ethnic differences in the impact of advanced maternal age on birth prevalence of Down syndrome.

OBJECTIVES: This study explored whether ethnic differences in the impact of advanced maternal age on the risk of Down syndrome might reflect differences in use of prenatal diagnostic technologies. METHODS: Maternal age-specific odds of Down syndrome and amniocentesis use were compared among African Americans, Mexican Americans, and non-Hispanic Whites via birth data for the years 1989 to 1991. RESULTS: The odds ratio and population attributable risk of Down syndrome due to maternal age of 35 years or older were highest for Mexican Americans, intermediate for African Americans, and lowest for non-Hispanic Whites. CONCLUSIONS: Advanced maternal age has a greater impact on the risk of Down syndrome for African American and, particularly, Mexican American women than for non-Hispanic White women. This difference in impact might reflect lower availability or use of prenatal diagnostic technologies.

Adult↗

If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?

The Magnesium and Neurologic Endpoints Trial was a randomized controlled trial (RCT) done to learn whether or not receiving magnesium sulfate during preterm labor could prevent cerebral palsy. Unexpectedly, in the tocolytic arms of the trial, seven (including one set of twins) of 46 cases assigned to receive magnesium ended in total pediatric mortality (fetal + neonatal + postneonatal), compared to none of 47 cases assigned to other tocolytics ending in death. The difference between the two treatment arms is highly statistically significant (risk difference 15.2%; 95% confidence interval 4.8, 25.6; P = .006). If this relationship is confirmed by experimentation with animals or through the conduct of a large RCT at other institutions, it is possible that tocolytic magnesium will be found to be associated with the deaths of several thousand newborns in the United States annually. If the true excess total pediatric mortality is 10%, and if magnesium accounts for 40% of all tocolytics used, then tocolytic magnesium increases the absolute number of infant deaths by about 4800 every year.

Fetal Death↗